

# Adrenal Steroidogenesis and Congenital Adrenal Hyperplasia



Adina F. Turcu, MD<sup>a</sup>, Richard J. Auchus, MD, PhD<sup>a,b,\*</sup>

## KEYWORDS

- Steroidogenesis • Congenital adrenal hyperplasia • 21-Hydroxylase • Androgen
- Steroid hydroxylase • Adrenal insufficiency • Ambiguous genitalia
- Disorder of sex development

## KEY POINTS

- Steroidogenesis in the adrenal gland reflects the zone-specific expression of enzymes, which comprise pathways to efficiently complete the biosynthesis of aldosterone, cortisol, and dehydroepiandrosterone sulfate.
- The most common form of congenital adrenal hyperplasia is 21-hydroxylase deficiency, in which a block in cortisol biosynthesis shifts precursors to pathways that make excess adrenal-derived androgens.
- Nonclassic 21-hydroxylase deficiency differs from the classic form in that cortisol deficiency and virilization of newborn girls are absent.
- Treatment of classic 21-hydroxylase deficiency consists of glucocorticoid and mineralocorticoid replacement, and for both classic and nonclassic disease, sufficient glucocorticoid is administered to correct the androgen excess.
- Patients with 21-hydroxylase deficiency are prone to developing adrenal cortical adenomas and myelolipomas as well as adrenal rest tumors in the testis or elsewhere.

## ADRENAL STEROIDOGENESIS

Adrenal steroidogenesis is a dynamic process, reliant on de novo synthesis, with no presynthesized hormones stored for immediate release. Cholesterol is the common precursor for all steroids and is efficiently converted along a series of steps to the final product. To initiate steroidogenesis, cholesterol is mobilized from a pool in the outer

---

The authors have nothing to disclose.

<sup>a</sup> Division of Metabolism, Endocrinology, & Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; <sup>b</sup> Department of Pharmacology, University of Michigan, Room 5560A MSRBII, 1150 West Medical Center Drive, Ann Arbor, MI 48109, USA

\* Corresponding author. Division of Metabolism, Endocrinology, & Diabetes, Department of Internal Medicine, University of Michigan, Room 5560A MSRBII, 1150 West Medical Center Drive, Ann Arbor, MI 48109.

E-mail address: [rauchus@med.umich.edu](mailto:rauchus@med.umich.edu)

Endocrinol Metab Clin N Am 44 (2015) 275–296

<http://dx.doi.org/10.1016/j.ecl.2015.02.002>

[endo.theclinics.com](http://endo.theclinics.com)

0889-8529/15/\$ – see front matter © 2015 Elsevier Inc. All rights reserved.

mitochondrial membrane (OMM),<sup>1</sup> which is replenished from cytosolic storage droplets of cholesterol esters. The steroidogenic acute regulatory (StAR) protein enables cholesterol transfer from the OMM to the inner mitochondrial membrane,<sup>2</sup> where the sidechain cleavage enzyme (CYP11A1, P450scc) catalyzes the first and rate-limiting step of steroidogenesis: the conversion of cholesterol to pregnenolone (Fig. 1A).<sup>1,3</sup>

### ***Aldosterone Biosynthesis***

Mineralocorticoid synthesis occurs in the zona glomerulosa (ZG) and requires the subsequent action of 3 enzymes: (1) 3 $\beta$ -hydroxysteroid dehydrogenase type 2 (HSD3B2), which performs the irreversible conversion of the hydroxyl group to a keto group on carbon 3 and simultaneous isomerization of the double bond from the  $\Delta^5$  to the  $\Delta^4$  position<sup>4</sup>; (2) 21-hydroxylase (CYP21A2, P450c21), which converts progesterone into 11-deoxycorticosterone; (3) aldosterone synthase (CYP11B2, P450c11AS), which catalyzes the final 3 steps of aldosterone synthesis: 11 $\beta$ -hydroxylation, 18-hydroxylation, and 18-methyl oxidation. The 18-aldehyde group, from which the name “aldosterone” derives, forms an intramolecular cyclic hemiacetal using the 11 $\beta$ -hydroxyl group, with loss of water.

The ZG is optimized for aldosterone synthesis: it is the only zone that has CYP11B2 and, in contrast, has little 17 $\alpha$ -hydroxylase/17,20-lyase (CYP17A1, P450c17), an enzyme that directs steroid substrates toward cortisol and androgens synthesis (see Fig. 1B).<sup>5</sup> Angiotensin 2 and high extracellular potassium are the main stimulators of aldosterone synthesis, via increased intracellular calcium.<sup>6</sup>

### ***Cortisol Biosynthesis***

The glucocorticoid cortisol is synthesized in the zona fasciculata (ZF) under the regulation of adrenocorticotropin (ACTH). CYP17A1 catalyzes the 17 $\alpha$ -hydroxylation of pregnenolone and progesterone with roughly equal efficiency, and this reaction leads to cortisol production. In addition, CYP17A1 subsequently cleaves the C17-C20 bond of 17-hydroxypregnenolone and to a much lesser degree of 17-hydroxyprogesterone (17OHP), which leads to 19-carbon (C<sub>19</sub>) steroids (see Fig. 1A). Both reactions occur in a single active site, but with different regulation, as discussed later. With the activities of HSD3B2 and CYP21A2, which perform reactions similar to those on the mineralocorticoid pathway, 17-hydroxysteroids are converted to 11-deoxycortisol. Last, 11 $\beta$ -hydroxylase (CYP11B1, P450c11 $\beta$ ), an enzyme closely related to CYP11B2, completes the synthesis of cortisol. In rodents and many small animals, the ZF lacks CYP17A1. Consequently, nascent progesterone is 21-hydroxylated and 11 $\beta$ -hydroxylated to yield corticosterone, which is the dominant glucocorticoid in these species, but it is ordinarily a minor product of the human adrenal.

### ***Adrenal Androgen Biosynthesis***

Adrenal C<sub>19</sub> steroids are synthesized in the zona reticularis (ZR). Dehydroepiandrosterone (DHEA) is converted to its sulfate (DHEAS), which is the most abundant adrenal steroid. CYP17A1 is the only enzyme required for DHEA synthesis from pregnenolone and for androstenedione (AD) synthesis from progesterone. Although CYP17A1 is present in both ZF and ZR, its 17,20-lyase reaction is enhanced approximately 10 times by the cofactor cytochrome *b*<sub>5</sub> (CYB5A), which is absent in the ZF (see Fig. 1B).<sup>7</sup> Sulfotransferase SULT2A1 conjugates DHEA to DHEAS, a steroid with an important role in the regulation of adrenal androgen synthesis.<sup>8</sup> The adrenal synthesizes small amounts of testosterone, by the action of 17 $\beta$ -hydroxysteroid dehydrogenase type 5 (17 $\beta$ HSD5, AKR1C3) on AD (see Fig. 1A).





Fig. 1. (A) Major adrenal steroid synthesis pathways. (B) Adrenal zonation and enzyme expression pattern. SUL2A1/STS, steroid sulfotransferase type 2A1.

ACTH is the primary stimulus of steroidogenesis in the ZR and is required for ZR development.<sup>9,10</sup> Additional growth factors have been postulated to regulate adrenal androgen synthesis and to control the development of the ZR, but these remain poorly understood. The ZR resembles the fetal adrenal, which provides the C<sub>19</sub> substrate for estrogen synthesis during pregnancy but involutes at birth. The ZR is only a few cells thick at birth but expands during childhood, leading to an increase in circulating DHEAS and the phenomenon of adrenarche, which manifests as the development of axillary and pubic hair. ZR function and serum DHEAS peak about age 25 and then gradually decline, falling to childhood values in the seventh or eighth decade of life.

### CONGENITAL ADRENAL HYPERPLASIA

#### *Definition and Classification*

Congenital adrenal hyperplasia (CAH) refers to a group of inherited enzymatic defects in cortisol biosynthesis. Impaired cortisol production relieves negative feedback to the hypothalamus and the pituitary gland, which in response amplify the secretion of corticotropin-releasing hormone (CRH) and ACTH, respectively, resulting in hyperplasia of the adrenal cortex. The spectrum of enzymatic deficiencies ranges from mild to complete and from a single activity to several activities. Steroid 21-hydroxylase deficiency (21OHD) accounts for greater than 90% of CAH cases.<sup>11</sup> Conventionally, 21OHD is dichotomized into classic and nonclassic forms, based on the presence or absence of cortisol insufficiency. The classic forms of 21OHD are further grouped into “salt wasting” and “simple virilizing” subtypes, depending on whether mineralocorticoid synthesis is sufficiently impaired to cause spontaneous hypotensive crises in the infant.

Other forms of CAH are summarized in [Table 1](#). For additional information, the reader is directed to recent reviews and articles on deficiencies in CYP17A1,<sup>12</sup> CYP11B1,<sup>13</sup> HSD3B2,<sup>14</sup> lipoid CAH,<sup>15</sup> cholesterol side-cleavage enzyme (P450scc),<sup>16</sup> and P450-oxidoreductase (POR).<sup>17</sup> This review further expands the discussion of 21OHD.

#### *Epidemiology*

Classic 21OHD occurs in 1 of 16,000 live births worldwide.<sup>18</sup> Nonclassic 21OHD is much more frequent, occurring in approximately 1 of 1000 Caucasians and more commonly in certain ethnic groups, such as Ashkenazi Jews (1:27), Hispanics (1:53), Yugoslavs (1:62), and Italians (1:300).<sup>19</sup> The reason classic 21OHD has a similar prevalence throughout most of the world is related to the structure of the RCCX locus, which contains the tandemly arranged RP protein kinase, C4, CYP21, and tenascin X genes, which are duplicated together, as a discrete genetic unit.

#### *Genetics*

All forms of CAH are inherited in a monogenic, autosomal-recessive pattern. Human CYP21A2 is encoded by the *CYP21A2* gene, on chromosome 6p21.3, within the HLA major histocompatibility complex and adjacent to the genes for the fourth component of complement.<sup>20–22</sup> Only 30 kb away resides the nonfunctional *CYP21A1P* pseudogene, which encodes a truncated, inactive enzyme. Both *CYP21A2* and *CYP21A1P* contain 10 exons, and the 2 genes share 98% homology. Most mutant 21OHD alleles result from intergenic recombinations and gene conversion events between the 2 CYP21A genes.<sup>23</sup> Complete deletions, large gene conversions, and nonsense or frame-shift mutations that completely ablate CYP21A2 activity typically result in salt-wasting forms of CAH. Mutations resulting in even 1% to 2% residual enzyme activity allow sufficient aldosterone production and lead to simple virilizing forms of CAH. Nonclassic 21OHD patients retain up to 20% of the enzyme

| Table 1<br>Rare forms of congenital adrenal hyperplasia   |                           |  |  |   |
|---|---------------------------|--|--|---|
| Defective Enzyme  | Gene/Chromosome           | Incidence and Populations                                | Clinical Features  | Laboratory Findings   |
| CYP11B1<br>(P450c11 $\beta$ )                             | <i>CYP11B1</i> /8q24.3    | 1:200,000 newborns<br>High prevalence in Moroccan Jews   | Hypertension in most patients; hypokalemia; hyperandrogenemia and virilization   | ↑: 11DOC, 11-deoxycortisol, AD, T<br>↓: aldosterone, cortisol   |
| 17-Hydroxylase/17,20-lyase<br>(P450c17)                   | <i>CYP17A1</i> /10q21-q22 | 1:50,000 newborns;<br>2nd most common CAH form in Brazil | Hypertension, hypokalemia, and hypogonadism; 46,XX: primary amenorrhea and absence of secondary sexual characteristics<br>46,XY: undervirilization, abdominal testes                     | ↑: progesterone, 11DOC, corticosterone; LH and FSH<br>↓: cortisol, DHEA, DHEAS, AD, T   |
| HSD3B2  | <i>HSD3B2</i> /1p13.1     | Rare   | Volume depletion, hyponatremia, and hyperkalemia<br>46,XX: mild clitoromegaly<br>46,XY: undervirilization from hypospadias to female-appearing   | ↑: $\Delta$ 5 steroids-pregnenolone, 17OH-pregnenolone, DHEA, DHEAS<br>↓: cortisol, aldosterone   |
| Steroidogenic acute regulatory protein (StAR, Lipoid CAH) | <i>STAR</i> /8p11.2       | More frequent in Japanese, Palestinians, Koreans         | Adrenal insufficiency; enlarged, lipid-laden adrenal glands. Female phenotype of external genitalia in both sexes  | All steroids decreased  |
| Cholesterol side-chain cleavage enzyme (P450scc)          | <i>CYP11A1</i> /15q23-q24 | Isolated cases reported                                  | Adrenal insufficiency; adrenal glands may appear absent  | All steroids decreased  |
| POR   | <i>POR</i> /7q11.2        | Rare; more common in Japan and Korea                     | Volume depletion, skeletal malformations (Antley-Bixler); maternal virilization<br>46,XX: mild-to-moderate virilization<br>46,XY: undervirilization from hypospadias to female-appearing | Highly variable profiles, multiple partial defects<br>↑: progesterone; 11DOC, corticosterone, 17OHP variably high<br>↓: cortisol, aldosterone, androgens, and estrogens |


**Abbreviations:** 11DOC, 11-deoxycorticosterone; AD, androstenedione; CYP11B1, 11 $\beta$ -hydroxylase; DHEAS, DHEA sulfate; DHEA, dehydroepiandrosterone; FSH, follicle-stimulating hormone; HSD3B2, 3 $\beta$ -hydroxysteroid dehydrogenase type 2; LH, luteinizing hormone; POR, P450-oxidoreductase deficiency; T, testosterone.

activity and do not have adrenal insufficiency. Nonclassic 21OHD patients may be either compound heterozygotes (with one classic allele and one nonclassic allele) or heterozygotes with 2 nonclassic alleles. Although the most severe and mildest forms of the disease tend to maintain some genotype-phenotype correlation, the intermediate forms are often poorly linked with specific gene defects, suggesting other contributors (genetic or environmental) to the phenotypical expression.<sup>23</sup>

### Biochemistry of 21-Hydroxylase Deficiency

As a result of 21-hydroxylase dysfunction, upstream steroid precursors accumulate and are diverted toward accessible pathways to form potent androgens (Fig. 2). Elevations of 17OHP, the main substrate of CYP21A2, are a hallmark of 21OHD, and 17OHP has traditionally been used for both diagnosis and monitoring of the disease. In addition, the CYP21A2 blockage promotes the buildup of other C<sub>21</sub> steroids. Human CYP17A1 hydroxylates pregnenolone and progesterone in position 17 with equal efficiencies, but also 16 $\alpha$ -hydroxylates up to 30% of progesterone.<sup>24</sup> In the normal pathways to aldosterone and cortisol, progesterone and 17OHP are first hydroxylated at position 21 by CYP21A2, and subsequently at other positions. In 21OHD, progesterone and 17OHP accumulate and are substrates for CYP11B1, leading to 11 $\beta$ -hydroxyprogesterone and 21-deoxycortisol (21dF), respectively.

The excess 17OHP resulting from CYP21A2 deficiency is diverted through the pathways left accessible, to form potent androgens, such as testosterone and 5 $\alpha$ -dihydrotestosterone (DHT). CYP17A1 mediates the conversion of 17-hydroxypregnenolone to DHEA ( $\Delta^5$  pathway) and of 17OHP to AD ( $\Delta^4$  pathway). The catalytic efficiency of the



**Fig. 2.** Pathways of steroid hormone synthesis in 21-OHD, including backdoor pathway and 11-oxygenated androgens. AD, androstenedione; AKR1C2,4, aldo-keto reductase types 1C2 and 1C4; CYB5A, cytochrome b<sub>5</sub>; CYP17A1, 17 $\alpha$ -hydroxylase/17,20-lyase; DHEA, dehydroepiandrosterone; HSD17B6, 17 $\beta$ -hydroxysteroid dehydrogenase type 6 (an oxidative 3 $\alpha$ -HSD); SRD5A1/2, 5 $\alpha$ -reductase, types 1 and 2; T, testosterone; 11OHA, 11 $\beta$ -hydroxyandrostenedione; 11OHT, 11 $\beta$ -hydroxytestosterone.

human 17,20-lyase, however, is approximately 100 times greater for the  $\Delta^5$  reaction, as compared with the  $\Delta^4$  reaction,<sup>25</sup> explaining the enormous 17OHP accumulation in 21OHD. In patients with 21OHD, significant AD synthesis might still occur via the  $\Delta^4$  pathway due to very high intra-adrenal 17OHP.

More recently, a third potential fate of 17OHP has been suggested in patients with 21OHD: androgen synthesis via the “backdoor pathway” (see Fig. 2). This pathway was initially described a decade ago in tammar wallabies, whose testes produce 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol (5 $\alpha$ Adiol) rather than testosterone.<sup>26</sup> The 17OHP is first 5 $\alpha$ -reduced, then 3 $\alpha$ -reduced, and only subsequently undergoes 17,20-lyase cleavage, to form androsterone. After 17 $\beta$ -reduction to 5 $\alpha$ Adiol, circulating 5 $\alpha$ Adiol is 3 $\alpha$ -oxidized to produce DHT in target tissues such as genital skin and prostate, thus bypassing the conventional androgens AD and testosterone as intermediates. This pathway might contribute to the virilization of female fetuses with CAH.<sup>27</sup> Kamrath and colleagues<sup>28</sup> were the first to demonstrate increased excretion of 5 $\alpha$ -reduced products and intermediates of the backdoor pathway in 142 patients with CAH between 1 and 25 years old, compared with 138 similarly aged controls. Using gas chromatography/mass spectrometry (MS), they found significantly increased urinary excretion of 5 $\alpha$ -pregnane-3 $\alpha$ ,17 $\alpha$ -diol-20-one, the critical intermediate and a specific marker of the backdoor pathway, in patients with 21OHD. Furthermore, they reported 7-fold elevations of urinary androsterone, the dominant 5 $\alpha$ -reduced C<sub>19</sub> steroid derived from both classical and backdoor pathways, in children and young adults with 21OHD. In contrast, they found only a 2-fold elevation in etiocholanolone, the 5 $\beta$ -reduced C<sub>19</sub> derived only from the classical pathways. Importantly, 5 $\alpha$ -/5 $\beta$ -reduced cortisol metabolites ratios were not different in controls and 21OHD, excluding a general increase in 5 $\alpha$ -reductase activity to explain their data.<sup>28</sup>

### **Diagnosis**

Diagnosis of 21OHD relies on elevated 17OHP, one of the direct substrates of the deficient enzyme. The 17OHP levels are reflective of disease severity. Most patients with classic 21OHD have 17OHP levels consistently greater than 10,000 ng/dL, whereas unaffected patients typically have baseline 17OHP values less than 200 ng/dL.<sup>29</sup> In nonclassic 21OHD, a random 17OHP is often equivocal, and post-cosyntropin values greater than 1000 ng/dL are required to make the diagnosis. A few nonclassic 21OHD patients who are compound heterozygotes for classic and nonclassic alleles will have stimulated 17OHP values greater than 10,000 ng/dL, but by definition, they lack clinically significant adrenal insufficiency, with stimulated cortisol values greater than 14  $\mu$ g/dL.

### **Newborn screening**

Screening of newborns for CAH is performed in all 50 states of the United States. Screening decreases time to diagnosis and improves morbidity and mortality,<sup>30–33</sup> particularly by preventing salt wasting crises. Male newborns with CAH are more likely to not be diagnosed early clinically, because they do not exhibit genital ambiguity at birth.

First-tier screening uses dried blood spots on standard screening cards and measures 17OHP by immunofluorometric assay (DELFA). A very high random 17OHP (>20,000 ng/dL) is diagnostic of 21OHD. False-positive results, however, are common in premature and severely ill infants.<sup>34,35</sup> Thus, weight and gestational age-adjusted cutoffs for 17OHP improve the positive predictive value of screening.<sup>36–38</sup> False negative rates of up to 22% have been reported in infant screening,<sup>39,40</sup> particularly when mothers had been exposed to glucocorticoids prenatally. Although false negative

results are reportedly more common in girls,<sup>40</sup> it is possible that missed boys remained unidentified, while the diagnosis was more likely to be pursued in girls, who are born with ambiguous genitalia.

Some of the limitations of immunoassay-based screening can be overcome by adjudicating positive tests with a second-tier assay using liquid chromatography/tandem MS(LC-MS/MS).<sup>41–43</sup> In addition to increased specificity, LC-MS/MS can also quantify multiple steroids with one measurement. Elevated 21dF by LC-MS/MS has been shown to increase the sensitivity of newborn screening<sup>42</sup> and better discriminate heterozygote carriers.<sup>44</sup> LC-MS/MS assays, however, are not widely available, are often time-consuming, and are prohibitively expensive for screening purposes currently.

#### **Diagnosis of 21-hydroxylase deficiency beyond infancy**

Patients evaluated for clinical evidence of inappropriate androgen excess initially undergo testing of 17OHP in an early morning serum sample.<sup>29</sup> The gold standard for diagnosing any form of CAH in patients with indeterminate values is a cosyntropin stimulation test, which maximizes the ratio between the steroids upstream and downstream the enzymatic blockage.<sup>45</sup> Fig. 3 shows suggested cutoff baseline and stimulated 17OHP values in patients with 21OHD. Genetic testing of *CYP21A2* detects 90% to 95% of mutant alleles<sup>46</sup> and is useful when steroid results are equivocal<sup>47</sup> or unreliable (hypopituitarism) and for genetic counseling, particularly in nonclassic 21OHD. Because other forms of CAH are not tested, the cost is high, and management is rarely changed, genetic testing is not routinely recommended.




Fig. 3. Schematic evaluation of 21OHD based on baseline and stimulated 17OHP values.

**Clinical Features**

**Salt wasting**

Approximately three-quarters of patients with classic 21OHD have aldosterone deficiency and thus are prone to volume depletion and hyperkalemia.<sup>48</sup> Where neonatal screening is not performed, undiagnosed male infants might present with failure to thrive and dehydration in the first 2 weeks of life, which can lead to death if not appropriately recognized and treated. All untreated classic 21OHD patients waste salt during illness, but spontaneous volume depletion in a well infant defines “salt-wasting” disease, a term that has little utility beyond childhood.

**Ambiguous genitalia and prenatal virilization**

Girls with classic 21OHD of all severities are born with varying degrees of genital ambiguity. Prenatal exposure to adrenal androgens activates the androgen receptors in genital skin, favors clitoral enlargement and labial fusion, and interferes with the urogenital sinus septation, which normally occurs at 7 weeks of gestation in girls. The degree of virilization is classified according to the 5-point Prader scale (Fig. 4). If virilization is severe (Prader 4–5), assignment to male sex of rearing might inadvertently occur, and in rare cases, parents choose to raise the child as a boy knowing the diagnosis.


Boys with classic 21OHD typically have normal male genitalia (Prader 5). Subtle findings, such as hyperpigmentation of the scrotum and enlarged phallus, might be present at birth.

**Postnatal virilization**

In inadequately treated classic 21OHD, the adrenal androgen excess promotes further clitoral growth in girls and phallus enlargement in boys. Children with nonclassic 21OHD may exhibit evidence of androgen excess at various ages, such as premature pubarche and oily skin, but not genital virilization. Poorly controlled adolescent girls might experience hirsutism, acne, and irregular menses, similarly with patients with polycystic ovarian syndrome (PCOS).<sup>48</sup>

**Growth**

Both male and female infants with classic 21OHD are longer than average at birth.<sup>49</sup> Increased circulating levels of sex steroids promote accelerated linear growth and bone maturation early in life, which results in below average final height, due to



**Fig. 4.** Prader scale, female external genitalia viewed from above (top) and in cross-section (bottom).

premature epiphyseal closure. In addition, glucocorticoid treatment, especially when excessive, suppresses growth. A meta-analysis of data from 35 centers concluded that the near-final height of patients with classic 21OHD was  $-1.38$  SD below the population mean and  $-1$  SD below the predicted mid-parental height.<sup>50</sup> A multitude of factors influence adult height, including severity of disease,<sup>51</sup> age at diagnosis,<sup>49</sup> treatment regimen,<sup>52,53</sup> and compliance. These known factors, however, failed to prove significant individually in pooled data, possibly because of heterogeneity and inconsistent reporting between studies. Both boys and girls can experience central precocious puberty when control is poor or erratic, thought to be due to adrenal-derived sex steroid “priming” and withdrawal, which further compromises adult height.

#### ***Psychosexual development***

Girls with classic 21OHD show more male-pattern play, activities, and career preferences.<sup>54,55</sup> In addition, some studies have found that affected girls display more aggressive behaviors and lower maternal drive as compared with their unaffected sisters.<sup>56,57</sup> Exposure to higher than normal androgens prenatally and in childhood is thought to “imprint” the brain, leading to masculine behavior but rarely to male gender identity if treated from birth.

Some studies suggest that female patients with 21OHD, particularly those with more severe forms, undergo malelike cognitive development, with higher visuospatial and logic performance and lower verbal abilities.<sup>58–60</sup> Data regarding the overall intelligence coefficient (IQ) of patients with 21OHD have been conflicting. It has been suggested that salt-wasting 21OHD might result in lower IQs, possibly because of electrolyte imbalances in infancy.<sup>61</sup> Conversely, other authors found no overall IQ or cross-gender performance differences between 21OHD patients and unaffected controls.<sup>62</sup>

#### ***Female reproduction***

Women with 21OHD have lower fertility rates, which correlate inversely with disease severity.<sup>63,64</sup> The live-birth rates in salt-wasting classic 21OHD have been reported to be only up to 10%, 33% to 50% in simple virilizing forms, and 63% to 90% in non-classic 21OHD, the latter rate being similar to that observed in the general population.<sup>65–69</sup> Hormonal, anatomic, and psychosocial factors have been suggested to contribute to impaired fertility.<sup>64</sup> Adrenal androgen overproduction can inhibit ovarian folliculogenesis and disturb the normal gonadotropin secretion pattern.<sup>69,70</sup> Elevated adrenal-derived progesterone in the follicular phase interferes with the normal menstrual cycle and impairs sperm penetration.<sup>66,71,72</sup> Women with 21OHD may also have excessive ovarian androgen production<sup>73,74</sup> and secondary PCOS.<sup>75</sup>

Nonhormonal contributors to decreased fertility in 21OHD women include distorted genital anatomy, such as vaginal stenosis and reduced clitoral sensitivity, as well as decreased sexual motivation<sup>67,76</sup> and lower maternal interest.<sup>54</sup> Nevertheless, in women with classical 21OHD who attempt pregnancy under skilled management, fecundity rates are normal.<sup>77</sup>

In contrast with the frequent development of adrenal rest tumors in the testes of men with 21OHD, ovarian adrenal rest tumors have only sporadically been reported in affected women.<sup>78–81</sup> This difference could be due to several factors, including more difficult distinction of ectopic adrenal tissue from theca cells in the heterogeneous ovary, the position of the ovaries in the pelvis, and possibly better control in most women, in whom undesirable clinical manifestations of androgen excess might provide motivation for compliance.

**Male reproduction**

Fertility in men with 21OHD has not been studied as extensively as in women. In the absence of newborn screening, boys with simple-virilizing 21OHD might remain undiagnosed, until they present with sexual precocity, accelerated growth, adrenal crisis during an infection, or rarely, after fathering an affected girl. Studies from the United Kingdom and Finland suggest that male fertility is well below that of the normal population.<sup>82,83</sup> The 2 main contributors to male infertility in 21OHD are hypogonadotropic hypogonadism, due to gonadal axis suppression from adrenal-derived androgens, and testicular adrenal rest tumors (TARTs).<sup>84,85</sup>

TARTs are typically bilateral masses, arising in the rete testes, thus often nonpalpable when small.<sup>84</sup> Ultrasound studies have identified TARTs in greater than 20% of boys<sup>86,87</sup> and up to 94% of adults with classic 21OHD.<sup>84,85,88</sup> Some, but not all TARTs, regress following intensified glucocorticoid treatment.<sup>89</sup> The variable response might be in part due to fibrotic changes<sup>90</sup> and to the number of adrenal-lineage cells, which migrated to the gonad during embryologic development.<sup>91</sup> TARTs may lead to obstruction of seminiferous tubules, gonadal dysfunction, and infertility.<sup>84</sup> Surgery to remove TARTs gives good long-term control of tumor growth and mass effect,<sup>92,93</sup> but rarely restores fertility or testicular testosterone production.<sup>93,94</sup> For this reason, medical therapy is continued as primary treatment as long as the luteinizing hormone (LH) is in the normal range, the rests are shrinking, and the testosterone is increasing, for at least 6 months and longer if tolerated. An increase in follicle-stimulating hormone (FSH) and a decrease in inhibin B indicate loss of Sertoli cell function and poor prognosis for restoration of testicular function. Abrupt resumption of tight disease control in patients with TARTs and suppressed testicular function will lower serum testosterone into the hypogonadal range. To enhance compliance, the patient should be warned of these changes, and a gradual increase in medication should be considered. TARTs rarely if ever occur in men with nonclassic 21OHD. Little is known about fertility in men with nonclassic 21OHD, because few are ever diagnosed, and men with unexplained infertility are rarely tested for 21OHD.

**Adrenal masses**

A high prevalence of benign adrenal masses has been reported in patients with 21OHD. Greater than 80% of homozygous and 45% of heterozygous patients had adrenal tumors in one study,<sup>95</sup> although no correlation between tumor size and serum 17OHP concentrations was found. Most tumors had a diameter of less than 2 cm, but several giant myelolipomas have also been reported, typically in patients who are chronically undertreated.<sup>96-98</sup>

**Metabolic abnormalities**

In a prospective cross-sectional study that followed 203 patients with CAH, 41% were obese, 46% had hypercholesterolemia, 29% were insulin-resistant, 40% had osteopenia, and 7% had osteoporosis.<sup>82</sup> Similar findings have been reported in smaller studies<sup>99-101</sup> and have been mostly attributed to glucocorticoid overtreatment.

**Management****Medical treatment**

Glucocorticoids and mineralocorticoids are the mainstays of treatment of 21OHD. Glucocorticoids exert 2 principal actions: replacement of the deficient cortisol and suppression of the adrenal androgen overproduction, by exerting negative feedback on the hypothalamus and the pituitary, which subsequently decreases CRH production and ACTH stimulation.

**Glucocorticoid replacement** Patients with classic 21OHD require chronic glucocorticoid replacement. Hydrocortisone is preferred in children and adolescents, until growth is completed, because of its short action, which limits the potential to suppress growth. A total of 10 to 17 mg/m<sup>2</sup> daily divided in 2 to 3 doses is typically recommended,<sup>29</sup> although it remains unclear if a specific dose distribution throughout the day has a significant clinical impact.<sup>102</sup> The lowest possible dose should be used to avoid growth suppression.<sup>51,53,103,104</sup>

Hydrocortisone also serves as replacement therapy for adults, but long-acting synthetic glucocorticoids are often preferred, owing to less frequent dosing. The longer duration of action and higher potency of drugs like prednisolone and dexamethasone, however, might increase the risk of detrimental effects, including weight gain, dermal atrophy, poor sleep, and bone loss.<sup>82,105–108</sup>

Available treatment options and suggested doses are shown in **Table 2**. Stress doses of steroids should be given in patients with classic 21OHD during surgery, physical illness, labor, and delivery.<sup>29</sup> In women attempting to conceive and during pregnancy, a glucocorticoid that is inactivated by placental 11 $\beta$ -hydroxysteroid dehydrogenase type 2 (eg, hydrocortisone, prednisone, and prednisolone) should be used, to avoid fetal exposure.

Asymptomatic patients with nonclassic 21OHD do not require treatment, and stress doses of steroids are rarely needed. Glucocorticoid treatment is primarily given to children with sexual precocity and advanced bone age or to women with infertility due to this condition. For other consequences of androgen excess, including acne, hirsutism, or body odor, alternative therapies include antiandrogens (spironolactone), oral contraceptives, and mechanical depilation. When treated, replacement regimens are similar to those prescribed to classic 21OHD patients with lower doses. One retrospective series found high rates of pregnancy loss in women with nonclassic 21OHD, but this rate was lower in women who were treated with glucocorticoids.<sup>109</sup> For this reason, glucocorticoids (hydrocortisone) are often continued throughout gestation, particularly in women who conceive while taking glucocorticoids.

The goals of therapy for classic 21OHD are to replace the hormonal deficits, while adequately suppressing the androgen excess. This balance is often hard to achieve without causing iatrogenic Cushing syndrome. Near-normalization of AD in both men and women and of testosterone in women indicates adequate control in most circumstances. Conversely, the 17OHP should not be consistently in the normal range: values of 1000 to 3000 ng/dL are acceptable if androgen production is controlled.<sup>110</sup> An exception is women attempting pregnancy, in whom treatment needs to be intensified to keep the follicular-phase progesterone suppressed (<0.6 ng/mL). Men with TARTs require at least one dose of a long-acting glucocorticoid to keep the ACTH suppressed and to allow regression.

**Table 2**  
Available corticoid formulations and suggested doses for adults

| Type of Steroid | Total Daily Dose (mg) | Number of Doses/d |
|-----------------|-----------------------|-------------------|
| Hydrocortisone  | 15–25                 | 2–3               |
| Prednisone      | 5–7.5                 | 2                 |
| Prednisolone    | 4–6                   | 2                 |
| Dexamethasone   | 0.25–0.5              | 1                 |
| Fludrocortisone | 0.05–0.2              | 1                 |

**Mineralocorticoid replacement** Mineralocorticoid replacement (fludrocortisone acetate, 0.1–0.3 mg daily) is necessary in patients with classic 21OHD. Infants with the most severe (salt-wasting) forms of disease need higher mineralocorticoid doses and additionally require supplementation with sodium chloride (1–2 g sodium chloride daily) while the renal function matures.<sup>111</sup> Mineralocorticoid replacement is generally maintained but occasionally becomes unnecessary in adults, possibly because of extra-adrenal 21-hydroxylation of adrenal-derived progesterone.<sup>112,113</sup> Mineralocorticoid replacement and restoration of euvolemia decrease vasopressin and ACTH secretion, which often lowers the dose of glucocorticoid required to achieve adequate control of androgen production.<sup>50,103</sup> The dose of fludrocortisone is titrated to achieve normal sitting and standing blood pressure without an orthostatic drop, plasma renin activity near the lower limit of the normal range, and normal serum potassium; reevaluations should occur periodically.

**Experimental therapy** Addition of the antiandrogen flutamide and the aromatase inhibitor testolactone allowed the use of lower doses of hydrocortisone and fludrocortisone acetate and normalized linear growth and bone maturation in children followed for 2 years.<sup>114,115</sup> Growth hormone, with or without a GnRH agonist, improved final height in some studies.<sup>116,117</sup> In addition, GnRH antagonist has been successful in improving height in children with 21OHD and precocious puberty.<sup>117</sup> Abiraterone acetate, a potent CYP17A1 inhibitor indicated for testosterone suppression in patients with prostate cancer, when added to physiologic doses of hydrocortisone and fludrocortisone acetate, normalizes AD in adult women with classic 21OHD and elevated androgens.<sup>118</sup> Extended-release hydrocortisone preparations, which might improve compliance and limit the need for more potent glucocorticoids, are being studied.<sup>119</sup> Long-term safety data on all of these agents are lacking, and large, randomized controlled studies are yet needed.

### **Surgical treatment**

**Reconstructive surgery** For girls with virilized genitalia, surgery has been used to normalize voiding and to enable vaginal intercourse, but no good evidence to support a specific timing for surgical correction exists. A multidisciplinary team gathering expertise from pediatric endocrinologists, surgeons, social workers, and psychologists should support the family into making an individualized decision. Advantages of early surgery include tissue malleability<sup>120</sup> and decreased psychological impact on both affected girls and parents.<sup>63,121</sup> A potential benefit of delaying surgery until adolescence or young adulthood is incorporating patient autonomy in the decision-making process.

A 2-step neurovascular-sparing clitoroplasty and vaginoplasty using total or partial urogenital mobilization is the preferred surgical approach, for minimizing clitoral insensitivity and urinary incontinence.<sup>29,122</sup> Good long-term outcomes data are difficult to obtain, due to the variations in surgical approach, baseline anatomy, hormonal control, and other mitigating factors. Postsurgical complications, such as urethra-vaginal fistulae, impaired sensation, and vaginal stenosis, have been described, and current procedures strive to minimize these complications. The evolution of urogenital function following these procedures is particularly critical for young women contemplating pregnancy.

**Elective adrenalectomy** Bilateral adrenalectomy has been performed in selected patients with severe forms of 21OHD, in whom hyperandrogenism was difficult to control despite generous glucocorticoid replacement or to avoid their associated side effects.<sup>123–125</sup> The ensuing primary adrenal insufficiency, however, is more tenuous than 21OHD and mandates strict adherence to lifelong glucocorticoid and

mineralocorticoid replacement, to prevent potentially fatal adrenal crises.<sup>125,126</sup> Complete absence of epinephrine and DHEA are additional theoretic concerns, but the consequences of these deficiencies remain unknown.

#### ***Prenatal diagnosis and treatment***

The goal of prenatal treatment is to prevent virilization of external genitalia in female fetuses with classic 21OHD. Administration of a glucocorticoid that is not degraded by the placenta, such as dexamethasone, suppresses fetal ACTH and the adrenal hyperandrogenism. Because virilization of affected female fetuses starts as soon as the sixth week of gestation,<sup>127</sup> treatment has to be initiated as soon as pregnancy is documented.<sup>128–131</sup> Treatment initiated after 9 weeks of gestation will be incompletely effective<sup>132</sup>; therefore, early diagnosis is required if prenatal treatment is desired. Chorionic villus sampling and rapid genotypic of fetal cells is performed at 11 weeks of gestation,<sup>133</sup> and treatment is discontinued if genetic testing reveals a male or unaffected female fetus. Screening for the most common *CYP21A2* mutations identifies approximately 90% of the affected patients,<sup>46</sup> but screening does not detect other forms of CAH. These procedures and treatments are costly and involve some risk to the mother. Earlier diagnosis appears to be possible by targeted massively parallel sequencing performed on cell-free fetal DNA circulating in maternal plasma at 5 weeks gestation,<sup>134,135</sup> and this approach might facilitate the decision of whom to treat.

Dexamethasone prevents or reduces virilization in greater than 85% of prenatally treated girls.<sup>132</sup> On the other hand, data regarding maternal and fetal long-term safety are scarce.<sup>136</sup> In the absence of a diagnosis when treatment must commence, 7 unaffected children receive treatment to prevent virilization in one affected female child on average. Parents should receive counseling regarding potential side effects and give informed consent to treatment. If elected, treatment from an experienced team in research centers that monitor outcomes is recommended.<sup>29</sup>

#### **SUMMARY AND FUTURE DIRECTIONS**

Adrenal biosynthesis of mineralocorticoids, glucocorticoids, and androgen precursors follow specific enzymatic cascades in distinct, concentric adrenal zones, a design that optimizes steroid production efficiency. CAH results from autosomal-recessive enzymatic defects in cortisol biosynthesis. The most common form is 21OHD, accounting for greater than 90% of CAH cases. The clinical spectrum ranges from severe or classic forms, of which 75% have both mineralocorticoid and glucocorticoid deficiency, to mild, nonclassic 21OHD, in which ACTH overstimulation compensates for the partial block in cortisol production. All forms are characterized by excessive adrenal androgen production, which parallels the severity of the enzymatic defect. Diagnosis of 21OHD is based on elevations of 17OHP and is included in standard newborn screening throughout the United States and many other countries. Although this approach is excellent in distinguishing the classic forms and unaffected individuals, it suffers from false positive and negative results and poorer discrimination of intermediate severity cases from heterozygote carriers. Incorporation of other steroids upstream the enzymatic defect, such as 21dF in the diagnostic panel, as well as wider use of second-tier MS assays, might increase sensitivity and specificity in future.

Glucocorticoids and, when needed, mineralocorticoids, are the mainstay of treatment in 21OHD. These treatments serve in replacing the deficient steroids as well as in suppressing the excessive adrenal androgen production. New treatments under study include sustained-release hydrocortisone and inhibitors of androgen biosynthesis. Balancing and accurately monitoring treatment remain clinically challenging. 17OHP, AD, and, in women, testosterone have been used for treatment adjustment,

but they do not always correlate well with clinical evidence of androgen excess. The identification and validation of adrenal-specific steroids and other molecules, which can be used clinically as biomarkers of adrenal-derived androgen production, would be of major clinical utility to facilitate treatment monitoring.

## REFERENCES

1. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocr Rev* 2011;32(1):81–151.
2. Clark BJ, Wells J, King SR, et al. The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). *J Biol Chem* 1994;269(45):28314–22.
3. Koritz SB, Kumar AM. On the mechanism of action of the adrenocorticotrophic hormone. The stimulation of the activity of enzymes involved in pregnenolone synthesis. *J Biol Chem* 1970;245(1):152–9.
4. Lachance Y, Luu-The V, Labrie C, et al. Characterization of human 3 $\beta$ -hydroxysteroid dehydrogenase/ $\Delta$ 5- $\Delta$ 4-isomerase gene and its expression in mammalian cells. *J Biol Chem* 1990;265(33):20469–75.
5. White PC. Disorders of aldosterone biosynthesis and action. *N Engl J Med* 1994;331(4):250–8.
6. Wang XL, Bassett M, Zhang Y, et al. Transcriptional regulation of human 11 $\beta$ -hydroxylase (hCYP11B1). *Endocrinology* 2000;141(10):3587–94.
7. Auchus RJ, Lee TC, Miller WL. Cytochrome b<sub>5</sub> augments the 17,20-lyase activity of human P450c17 without direct electron transfer. *J Biol Chem* 1998;273(6):3158–65.
8. Noordam C, Dhir V, McNelis JC, et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. *N Engl J Med* 2009;360(22):2310–8.
9. Reiter EO, Fuldauer VG, Root AW. Secretion of the adrenal androgen, dehydroepiandrosterone sulfate, during normal infancy, childhood, and adolescence, in sick infants, and in children with endocrinologic abnormalities. *J Pediatr* 1977;90(5):766–70.
10. Rosenfield RL, Grossman BJ, Ozoa N. Plasma 17-ketosteroids and testosterone in prepubertal children before and after ACTH administration. *J Clin Endocrinol Metab* 1971;33(2):249–53.
11. Speiser PW, White PC. Congenital adrenal hyperplasia. *N Engl J Med* 2003;349(8):776–88.
12. Auchus RJ. Genetic deficiencies of cytochrome P450c17 (CYP17A1): combined 17-hydroxylase/17,20-lyase and isolated 17,20-lyase deficiency. In: New M, editor. *Genetic steroid disorders*. Waltham (MA): Elsevier; 2014. p. 111–23.
13. Krone N, Riepe FG, Gotze D, et al. Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene. *J Clin Endocrinol Metab* 2005;90(6):3724–30.
14. Pang S. Congenital adrenal hyperplasia owing to 3 $\beta$ -hydroxysteroid dehydrogenase deficiency. *Endocrinol Metab Clin North Am* 2001;30(1):81–99, vi–vii.
15. Bose HS, Sugawara T, Strauss JF 3rd, et al. International congenital lipid adrenal hyperplasia C. The pathophysiology and genetics of congenital lipid adrenal hyperplasia. *N Engl J Med* 1996;335(25):1870–8.
16. Parajes S, Chan AO, But WM, et al. Delayed diagnosis of adrenal insufficiency in a patient with severe penoscrotal hypospadias due to two novel P450 side-

- change cleavage enzyme (CYP11A1) mutations (p.R360W; p.R405X). *Eur J Endocrinol* 2012;167(6):881–5.
17. Krone N, Dhir V, Ivison HE, et al. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. *Clin Endocrinol* 2007;66(2):162–72.
  18. Therrell BL. Newborn screening for congenital adrenal hyperplasia. *Endocrinol Metab Clin North Am* 2001;30(1):15–30.
  19. Speiser PW, Dupont B, Rubinstein P, et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. *Am J Hum Genet* 1985;37(4):650–67.
  20. Carroll MC, Campbell RD, Porter RR. Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. *Proc Natl Acad Sci U S A* 1985;82(2):521–5.
  21. White PC, Grossberger D, Onufer BJ, et al. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. *Proc Natl Acad Sci U S A* 1985;82(4):1089–93.
  22. White PC, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. *Proc Natl Acad Sci U S A* 1986;83(14):5111–5.
  23. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Endocr Rev* 2000;21(3):245–91.
  24. Swart AC, Storbeck KH, Swart P. A single amino acid residue, Ala 105, confers 16 $\alpha$ -hydroxylase activity to human cytochrome P450 17 $\alpha$ -hydroxylase/17,20 lyase. *J Steroid Biochem Mol Biol* 2010;119(3–5):112–20.
  25. Fluck CE, Miller WL, Auchus RJ. The 17, 20-lyase activity of cytochrome P450c17 from human fetal testis favors the  $\Delta^5$  steroidogenic pathway. *J Clin Endocrinol Metab* 2003;88(8):3762–6.
  26. Wilson JD, Auchus RJ, Leihy MW, et al. 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol is formed in tammar wallaby pouch young testes by a pathway involving 5 $\alpha$ -pregnane-3 $\alpha$ ,17 $\alpha$ -diol-20-one as a key intermediate. *Endocrinology* 2003;144(2):575–80.
  27. Auchus RJ. The backdoor pathway to dihydrotestosterone. *Trends Endocrinol Metab* 2004;15(9):432–8.
  28. Kamrath C, Hochberg Z, Hartmann MF, et al. Increased activation of the alternative “backdoor” pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. *J Clin Endocrinol Metab* 2012;97(3):E367–75.
  29. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2010;95(9):4133–60.
  30. Balsamo A, Cacciari E, Piazzzi S, et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. *Pediatrics* 1996;98(3 Pt 1):362–7.
  31. Brosnan PG, Brosnan CA, Kemp SF, et al. Effect of newborn screening for congenital adrenal hyperplasia. *Arch Pediatr Adolesc Med* 1999;153(12):1272–8.
  32. Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. *Pediatrics* 1998;101(4 Pt 1):583–90.
  33. Thil'en A, Nordenstrom A, Hagenfeldt L, et al. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. *Pediatrics* 1998;101(4):E11.
  34. Cavarzere P, Samara-Boustani D, Flechtner I, et al. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia. *Eur J Endocrinol* 2009;161(2):285–92.
  35. Coulm B, Coste J, Tardy V, et al. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in

- mainland France between 1996 and 2003. *Arch Pediatr Adolesc Med* 2012; 166(2):113–20.
36. Steigert M, Schoenle EJ, Biason-Lauber A, et al. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. *J Clin Endocrinol Metab* 2002;87(9):4106–10.
  37. Olgemoller B, Roscher AA, Liebl B, et al. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. *J Clin Endocrinol Metab* 2003;88(12):5790–4.
  38. van der Kamp HJ, Oudshoorn CG, Elvers BH, et al. Cutoff levels of 17 $\alpha$ -hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. *J Clin Endocrinol Metab* 2005;90(7):3904–7.
  39. Sarafoglou K, Banks K, Kyllö J, et al. Cases of congenital adrenal hyperplasia missed by newborn screening in Minnesota. *JAMA* 2012;307(22):2371–4.
  40. Varness TS, Allen DB, Hoffman GL. Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls. *J Pediatr* 2005;147(4):493–8.
  41. Schwarz E, Liu A, Randall H, et al. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. *Pediatr Res* 2009;66(2):230–5.
  42. Janzen N, Peter M, Sander S, et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. *J Clin Endocrinol Metab* 2007;92(7):2581–9.
  43. Janzen N, Sander S, Terhardt M, et al. Fast and direct quantification of adrenal steroids by tandem mass spectrometry in serum and dried blood spots. *J Chromatogr B Analyt Technol Biomed Life Sci* 2008;861(1):117–22.
  44. Costa-Barbosa FA, Tonetto-Fernandes VF, Carvalho VM, et al. Superior discriminating value of ACTH-stimulated serum 21-deoxycortisol in identifying heterozygote carriers for 21-hydroxylase deficiency. *Clin Endocrinol* 2010;73(6):700–6.
  45. New MI, Lorenzen F, Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. *J Clin Endocrinol Metab* 1983;57(2):320–6.
  46. Finkelstein GP, Chen W, Mehta SP, et al. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2011;96(1):E161–72.
  47. Nordenstrom A, Thilen A, Hagenfeldt L, et al. Genotyping is a valuable diagnostic complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 1999;84(5):1505–9.
  48. White PC, Bachega TA. Congenital adrenal hyperplasia due to 21 hydroxylase deficiency: from birth to adulthood. *Semin Reprod Med* 2012;30(5):400–9.
  49. Jaaskelainen J, Voutilainen R. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. *Pediatr Res* 1997; 41(1):30–3.
  50. Muthusamy K, Elamin MB, Smushkin G, et al. Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. *J Clin Endocrinol Metab* 2010;95(9):4161–72.
  51. Manoli I, Kanaka-Gantenbein C, Voutetakis A, et al. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. *Clin Endocrinol* 2002;57(5):669–76.

52. Kirkland RT, Keenan BS, Holcombe JH, et al. The effect of therapy on mature height in congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1978;47(6):1320–4.
53. Grigorescu-Sido A, Bettendorf M, Schulze E, et al. Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome. *Horm Res* 2003; 60(2):84–90.
54. Dittmann RW, Kappes MH, Kappes ME, et al. Congenital adrenal hyperplasia. I: gender-related behavior and attitudes in female patients and sisters. *Psychoneuroendocrinology* 1990;15(5–6):401–20.
55. Berenbaum SA. Effects of early androgens on sex-typed activities and interests in adolescents with congenital adrenal hyperplasia. *Horm Behav* 1999;35(1): 102–10.
56. Berenbaum SA, Resnick SM. Early androgen effects on aggression in children and adults with congenital adrenal hyperplasia. *Psychoneuroendocrinology* 1997;22(7):505–15.
57. Mathews GA, Fane BA, Conway GS, et al. Personality and congenital adrenal hyperplasia: possible effects of prenatal androgen exposure. *Horm Behav* 2009;55(2):285–91.
58. Helleday J, Bartfai A, Ritzen EM, et al. General intelligence and cognitive profile in women with congenital adrenal hyperplasia (CAH). *Psychoneuroendocrinology* 1994;19(4):343–56.
59. Kelso WM, Nicholls ME, Warne GL, et al. Cerebral lateralization and cognitive functioning in patients with congenital adrenal hyperplasia. *Neuropsychology* 2000;14(3):370–8.
60. Mueller SC, Temple V, Oh E, et al. Early androgen exposure modulates spatial cognition in congenital adrenal hyperplasia (CAH). *Psychoneuroendocrinology* 2008;33(7):973–80.
61. Johannsen TH, Ripa CP, Reinisch JM, et al. Impaired cognitive function in women with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2006; 91(4):1376–81.
62. Malouf MA, Migeon CJ, Carson KA, et al. Cognitive outcome in adult women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Horm Res* 2006;65(3):142–50.
63. Nordenskjold A, Holmdahl G, Frisen L, et al. Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2008;93(2):380–6.
64. Stikkelbroeck NM, Hermus AR, Braat DD, et al. Fertility in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Obstet Gynecol Surv* 2003;58(4):275–84.
65. Jaaskelainen J, Hippelainen M, Kiekara O, et al. Child rate, pregnancy outcome and ovarian function in females with classical 21-hydroxylase deficiency. *Acta Obstet Gynecol Scand* 2000;79(8):687–92.
66. Helleday J, Siwers B, Ritzen EM, et al. Subnormal androgen and elevated progesterone levels in women treated for congenital virilizing 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 1993;76(4):933–6.
67. Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *N Engl J Med* 1987; 316(4):178–82.
68. Klingensmith GJ, Garcia SC, Jones HW, et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. *J Pediatr* 1977;90(6):996–1004.

69. Feldman S, Billaud L, Thalabard JC, et al. Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 1992;74(3):635–9.
70. Hughes IA, Read GF. Menarche and subsequent ovarian function in girls with congenital adrenal hyperplasia. *Horm Res* 1982;16(2):100–6.
71. Holmes-Walker DJ, Conway GS, Honour JW, et al. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Clin Endocrinol* 1995;43(3):291–6.
72. Rosenfield RL, Bickel S, Razdan AK. Amenorrhea related to progestin excess in congenital adrenal hyperplasia. *Obstet Gynecol* 1980;56(2):208–15.
73. Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. *J Clin Endocrinol Metab* 1994;79(5):1328–33.
74. Ghizzoni L, Virdis R, Vottero A, et al. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 1996;81(2):601–6.
75. Hague WM, Adams J, Rodda C, et al. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. *Clin Endocrinol* 1990;33(4):501–10.
76. Kuhnle U, Bullinger M, Schwarz HP. The quality of life in adult female patients with congenital adrenal hyperplasia: a comprehensive study of the impact of genital malformations and chronic disease on female patients life. *Eur J Pediatr* 1995;154(9):708–16.
77. Casteras A, De Silva P, Rumsby G, et al. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. *Clin Endocrinol* 2009;70(6):833–7.
78. Al-Ahmadie HA, Stanek J, Liu J, et al. Ovarian 'tumor' of the adrenogenital syndrome: the first reported case. *Am J Surg Pathol* 2001;25(11):1443–50.
79. Russo G, Paesano P, Taccagni G, et al. Ovarian adrenal-like tissue in congenital adrenal hyperplasia. *N Engl J Med* 1998;339(12):853–4.
80. Zaarour MG, Atallah DM, Trak-Smayra VE, et al. Bilateral ovary adrenal rest tumor in a congenital adrenal hyperplasia following adrenalectomy. *Endocr Pract* 2014;20(4):e69–74.
81. Tiosano D, Vlodaysky E, Filmar S, et al. Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy. *Horm Res Paediatr* 2010;74(3):223–8.
82. Arit W, Willis DS, Wild SH, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. *J Clin Endocrinol Metab* 2010;95(11):5110–21.
83. Jaaskelainen J, Kiekara O, Hippelainen M, et al. Pituitary gonadal axis and child rate in males with classical 21-hydroxylase deficiency. *J Endocrinol Invest* 2000;23(1):23–7.
84. Stikkelbroeck NM, Otten BJ, Pasic A, et al. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2001;86(12):5721–8.
85. Stikkelbroeck NM, Suliman HM, Otten BJ, et al. Testicular adrenal rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and MR features. *Eur Radiol* 2003;13(7):1597–603.

86. Martínez-Aguayo A, Rocha A, Rojas N, et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2007;92(12):4583–9.
87. Claahsen-van der Grinten HL, Sweep FC, Blickman JG, et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Eur J Endocrinol* 2007;157(3):339–44.
88. Falhammar H, Nystrom HF, Ekstrom U, et al. Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia. *Eur J Endocrinol* 2012;166(3):441–9.
89. Rutgers JL, Young RH, Scully RE. The testicular “tumor” of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. *Am J Surg Pathol* 1988;12(7):503–13.
90. Claahsen-van der Grinten HL, Otten BJ, Stikkelbroeck MM, et al. Testicular adrenal rest tumours in congenital adrenal hyperplasia. *Best Pract Res Clin Endocrinol Metab* 2009;23(2):209–20.
91. Reisch N, Rottenkolber M, Greifenstein A, et al. Testicular adrenal rest tumors develop independently of long-term disease control: a longitudinal analysis of 50 adult men with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2013;98(11):E1820–6.
92. Ashley RA, McGee SM, Isotaolo PA, et al. Clinical and pathological features associated with the testicular tumor of the adrenogenital syndrome. *J Urol* 2007;177(2):546–9 [discussion: 549].
93. Walker BR, Skoog SJ, Winslow BH, et al. Testis sparing surgery for steroid unresponsive testicular tumors of the adrenogenital syndrome. *J Urol* 1997;157(4):1460–3.
94. Claahsen-van der Grinten HL, Otten BJ, Takahashi S, et al. Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. *J Clin Endocrinol Metab* 2007;92(2):612–5.
95. Jaresch S, Kornely E, Kley HK, et al. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1992;74(3):685–9.
96. Nerموen I, Rorvik J, Holmedal SH, et al. High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency. *Clin Endocrinol* 2011;75(6):753–9.
97. German-Mena E, Zibari GB, Levine SN. Adrenal myelolipomas in patients with congenital adrenal hyperplasia: review of the literature and a case report. *Endocr Pract* 2011;17(3):441–7.
98. McGeoch SC, Olson S, Krukowski ZH, et al. Giant bilateral myelolipomas in a man with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2012;97(2):343–4.
99. Reisch N, Arlt W, Krone N. Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Horm Res Paediatr* 2011;76(2):73–85.
100. Falhammar H, Filipsson H, Holmdahl G, et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2007;92(1):110–6.
101. Mooij CF, Kroese JM, Claahsen-van der Grinten HL, et al. Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia? *Clin Endocrinol* 2010;73(2):137–46.

102. German A, Suraiya S, Tenenbaum-Rakover Y, et al. Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. *J Clin Endocrinol Metab* 2008;93(12):4707–10.
103. Balsamo A, Cicognani A, Baldazzi L, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2003;88(12):5680–8.
104. Bonfig W, Pozza SB, Schmidt H, et al. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. *J Clin Endocrinol Metab* 2009;94(10):3882–8.
105. Horrocks PM, London DR. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. *Clin Endocrinol* 1987;27(6):635–42.
106. Young MC, Hughes IA. Dexamethasone treatment for congenital adrenal hyperplasia. *Arch Dis Child* 1990;65(3):312–4.
107. El-Maouche D, Collier S, Prasad M, et al. Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Clin Endocrinol* 2014;82(3):330–7.
108. Falhammar H, Filipsson Nystrom H, Wedell A, et al. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. *Eur J Endocrinol* 2013;168(3):331–41.
109. Bidet M, Bellanne-Chantelot C, Galand-Portier MB, et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2010;95(3):1182–90.
110. Auchus RJ. Congenital adrenal hyperplasia in adults. *Curr Opin Endocrinol Diabetes Obes* 2010;17(3):210–6.
111. Mullis PE, Hindmarsh PC, Brook CG. Sodium chloride supplement at diagnosis and during infancy in children with salt-losing 21-hydroxylase deficiency. *Eur J Pediatr* 1990;150(1):22–5.
112. Gomes LG, Huang N, Agrawal V, et al. Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2009;94(1):89–95.
113. Speiser PW, Agdere L, Ueshiba H, et al. Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. *N Engl J Med* 1991;324(3):145–9.
114. Laue L, Merke DP, Jones JV, et al. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1996;81(10):3535–9.
115. Merke DP, Keil MF, Jones JV, et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2000;85(3):1114–20.
116. Quintos JB, Vogiatzi MG, Harbison MD, et al. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2001;86(4):1511–7.
117. Lin-Su K, Vogiatzi MG, Marshall I, et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2005;90(6):3318–25.
118. Auchus RJ, Buschur EO, Chang AY, et al. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2014;99(8):2763–70.

119. Verma S, Vanryzin C, Sinaii N, et al. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. *Clin Endocrinol* 2010;72(4):441–7.
120. Bernbaum JC, Umbach DM, Ragan NB, et al. Pilot studies of estrogen-related physical findings in infants. *Environ Health Perspect* 2008;116(3):416–20.
121. Wisniewski AB, Migeon CJ, Malouf MA, et al. Psychosexual outcome in women affected by congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Urol* 2004;171(6 Pt 1):2497–501.
122. Pena A. Total urogenital mobilization—an easier way to repair cloacas. *J Pediatr Surg* 1997;32(2):263–7 [discussion: 267–8].
123. Gunther DF, Bukowski TP, Ritzen EM, et al. Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies. *J Clin Endocrinol Metab* 1997;82(10):3324–7.
124. Bruining H, Bootsma AH, Koper JW, et al. Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2001;86(2):482–4.
125. Van Wyk JJ, Ritzen EM. The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2003;88(7):2993–8.
126. Ogilvie CM, Rumsby G, Kurzwinski T, et al. Outcome of bilateral adrenalectomy in congenital adrenal hyperplasia: one unit's experience. *Eur J Endocrinol* 2006;154(3):405–8.
127. Witchel SF, Miller WL. Prenatal treatment of congenital adrenal hyperplasia—not standard of care. *J Genet Couns* 2012;21(5):615–24.
128. Forest MG, Betuel H, David M. Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. *Endocr Res* 1989;15(1–2):277–301.
129. Mercado AB, Wilson RC, Cheng KC, et al. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 1995;80(7):2014–20.
130. Evans MI, Chrousos GP, Mann DW, et al. Pharmacologic suppression of the fetal adrenal gland in utero. Attempted prevention of abnormal external genital masculinization in suspected congenital adrenal hyperplasia. *JAMA* 1985;253(7):1015–20.
131. David M, Forest MG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. *J Pediatr* 1984;105(5):799–803.
132. New MI, Carlson A, Obeid J, et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. *J Clin Endocrinol Metab* 2001;86(12):5651–7.
133. New MI, Abraham M, Yuen T, et al. An update on prenatal diagnosis and treatment of congenital adrenal hyperplasia. *Semin Reprod Med* 2012;30(5):396–9.
134. Barinaga M. Technical advances power neuroscience. *Science* 1990;250(4983):908–9.
135. New MI, Tong YK, Yuen T, et al. Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. *J Clin Endocrinol Metab* 2014;99(6):E1022–30.
136. Merce Fernandez-Balsells M, Muthusamy K, Smushkin G, et al. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses. *Clin Endocrinol* 2010;73(4):436–44.